Takeaways: Boey gives Allergan Aesthetics a differentiated entry point in Canadian aesthetics: a fast-onset, short-duration botulinum option that can attract first-time or co...
Takeaways: Zasocitinib’s Phase 3 win over deucravacitinib suggests it could become a best-in-class oral TYK2 option for moderate-to-severe plaque psoriasis if regulators...
Takeaways: The positive recommendation from CDA-AMC, backed by Phase III BE HEARD I and II trials, should accelerate payer negotiations and improve access for patients with chronic, pa...
Takeaways: If approved, FILSUVEZ would become Canada’s first treatment specifically for EB-related wounds, addressing a severe unmet need for patients with chronic, painful skin breakdown and he...
